Liberty Wealth Management LLC Sells 1,370 Shares of Johnson & Johnson (NYSE:JNJ)

Liberty Wealth Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 39.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,100 shares of the company’s stock after selling 1,370 shares during the quarter. Liberty Wealth Management LLC’s holdings in Johnson & Johnson were worth $332,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Christopher J. Hasenberg Inc bought a new position in Johnson & Johnson during the first quarter valued at $31,000. Keener Financial Planning LLC bought a new position in Johnson & Johnson during the fourth quarter valued at $40,000. WFA Asset Management Corp lifted its position in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Johnson & Johnson during the fourth quarter valued at $44,000. Finally, Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $45,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several analyst reports. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. The Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.

View Our Latest Analysis on JNJ

Johnson & Johnson Trading Up 1.6 %

NYSE:JNJ opened at $149.41 on Thursday. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm has a market cap of $359.58 billion, a P/E ratio of 9.31, a P/E/G ratio of 2.42 and a beta of 0.52. The firm has a 50-day simple moving average of $147.93 and a 200-day simple moving average of $153.56.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.68 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. The ex-dividend date of this dividend was Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.